A new class of anti-HIV therapy and new challenges.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice.European journal of medical research · 2010
   Trial
2. Repurposing screen identifies novel candidates for broad-spectrum coronavirus antivirals and druggable host targets.Antimicrobial agents and chemotherapy · 2024
   Article
3. Targeting chemokines for acute lymphoblastic leukemia therapy.Journal of hematology & oncology · 2021
   Review
4. Approved Antiviral Drugs over the Past 50 Years.Clinical microbiology reviews · 2016
   Review
5. Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.Drugs · 2010
   Review
6. Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease--indication of an evolving epidemic in West Africa.Retrovirology · 2010
   Article
7. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic.Antiviral research · 2010
   Review

Corrections and comments

• Comment on
  Maraviroc for previously treated patients with R5 HIV-1 infection.2008
• Comment on
  Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.2008

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as